RemeGen Co., Ltd. (OTCMKTS:REGMF) Sees Large Decline in Short Interest

RemeGen Co., Ltd. (OTCMKTS:REGMF) was the recipient of a significant drop in short interest in the month of January. As of January 30th, there was short interest totaling 70,500 shares, a drop of 62.9% from the January 15th total of 190,000 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.

RemeGen Price Performance

REGMF opened at $10.45 on Wednesday. The business has a fifty day moving average price of $10.05 and a 200 day moving average price of $8.89. RemeGen has a 12 month low of $9.81 and a 12 month high of $15.91.

About RemeGen

RemeGen Co, Ltd. is a Shanghai-based biopharmaceutical company focused on the research, development and commercialization of innovative antibody-based therapeutics for oncology and immunology. Since its founding in 2009, RemeGen has built a portfolio of antibody–drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies aimed at addressing a range of solid tumors and immune-related conditions. The company leverages its in-house discovery, engineering and manufacturing capabilities to advance its pipeline from preclinical stages through clinical trials.

RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is a HER2-targeting ADC that has received regulatory approval in China for HER2-positive gastric cancer and urothelial carcinoma.